Adenosine A2a receptor agonists as regulators of inflammation: pharmacology and therapeutic opportunities

References

• Fredholm BB Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14:1315–1323.
   Web of Science ®Google Scholar
• Fredholm BB, IJzerman AP, Jacobson KA, et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53(4):527–552.
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Kramer SB, Weissmann G, et al. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med. 1983:158:1160–1177.
   Web of Science ®Google Scholar
• Cronstein BN, Rosenstein ED, Kramer SB, et al. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J Immunol. 1985: 135:1366–1371.
   PubMed Web of Science ®Google Scholar
• Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001;41:775–787.
   PubMed Web of Science ®Google Scholar
• Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in down-regulation of inflammation and protection from tissue damage. Nature. 2001;414:916–920.
   PubMed Web of Science ®Google Scholar
• Sitovsky MV. Use of the A2a adenosine receptor as physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol. 2003;65:493–501.
   Web of Science ®Google Scholar
• Sitovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxiainducible factors and adenosine A2a receptors. Annu Rev Immunol. 2004;22:657–682.
   Web of Science ®Google Scholar
• Lappas CM, Sullivan GW, Linden J. Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs. 2005;14:797–806.
   PubMed Web of Science ®Google Scholar
• Palmer TM, Trevethick MA. Suppression of inflammatory and immune responses by the A2a adenosine receptor: an introduction. Br J Pharmacol. 2008;153 Suppl 1:S27–S34.
   Google Scholar
• Haskó G, Pcher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol. 2008;83(3):447–455.
   PubMed Web of Science ®Google Scholar
• Hutchinson AJ, Webb RL, Oei HH, et al. CGS21680, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J Pharmacol Exp Ther. 1989;251:47–55.
   PubMed Web of Science ®Google Scholar
• Rieger JM, Brown ML, Sullivan GW, et al. Design, synthesis, and evaluation of novel A2A adenosine receptor agonists. J Med Chem. 2001;44:531–539.
   PubMed Web of Science ®Google Scholar
• Neustadt BR, Hao J, Lindo N, et al. Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e-]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett. 2007:1376–1380.
   Google Scholar
• Ledent C, Vangeois JM, Schiffmann SN, et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine receptor A2a. Nature. 1997;338:674–678.
   Google Scholar
• Fredholm BB, Chern Y, Franco R, et al. Aspects of the general biology of adenosine A2A signalling. Prog Neurobiol. 2007;83:263–276.
   PubMed Web of Science ®Google Scholar
• Mayr B, Montminy M. T ranscriptional regulation by the pho sphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2:599–609.
   PubMed Web of Science ®Google Scholar
• Lin MC, Almus-Jacobs F, Chen HH, et al. Shear stress induction of the tissue factor gene. J Clin Invest. 1997;99:737–744.
   PubMed Web of Science ®Google Scholar
• Bshesh K, Zhao B, Spight D, et al. The A2a receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. J Leukoc Biol. 2002;72:1027–1036.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li J, Khoury J, et al. Adenosine signaling mediates SUMO-1 modification of I {kappa} B {alpha} during hypoxia and reoxygenation. J Biol Chem. 2009;284 (20):13686–13695.
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Springett GM, Monchizuki N, et al. A family of cAMP-binding proteins that directly activate Rap1. Science. 1998;282:2275–2279.
   PubMed Web of Science ®Google Scholar
• Sands WA, Woolson HD, Milne GR, et al. Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signalling 3 (SOCS-3) in vascular endothelial cells. Mol Cell Biol. 2006;26:6333–6346.
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signaling and immune regulation. Nat Rev Immunol. 2007;7:454–465.
   PubMed Web of Science ®Google Scholar
• Yarwood SJ, Borland G, Sands WA, et al. Identification of CCAAT/ enhancer-binding proteins as exchange protein activated transcription factors that mediate the induction of the SOCS-3 gene. J Biol Chem. 2008;283:6843–6853.
   Web of Science ®Google Scholar
• Khoa ND, Montesinos MC, Reiss AB, et al. Inflammatory cytokines regulate function and expression of adensoine A2A receptors in human monocytic THP-1 cells. J Immunol. 2001;167:4026–4032.
   Google Scholar
• Murphee LJ, Sullivan GW, Marshall MA, et al. Lipolpolysaccharide rapidly modify adenosine receptor transcripts in murine and human macrophages: role of NF-kB in A2a adenosine receptor induction. Biochem J. 2005;391:575–580.
   Web of Science ®Google Scholar
• Capecchi PL, Camurri A, Pompella G, et al. Up-regulation of A2A adenosine receptor expression by TNF-alpha in PBMC of patients with CHF: a regulatory mechanism of inflammation. J Card Fail. 2005;11(1):67–73.
   Web of Science ®Google Scholar
• Morello S, Ito K, Yamamura S, et al. IL-1 beta and TNF -alpha regulation of the adenosine receptor (A2A) expression: differential requirement for NF-kappa B binding to the proximal promoter. J Immunol. 2006;177 (10):7173–7183.
   PubMed Web of Science ®Google Scholar
• Sullivan GW, Carper HT, Mandell GL. The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity. Int J Immunopharmacol. 1995;17(10):793–803.
   Web of Science ®Google Scholar
• Hasko G, Pacher P, Deitch EA, et al. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther. 2007;113:264–275.
   PubMed Web of Science ®Google Scholar
• Sands WA, Martin AF, Strong EW, et al. Specific inhibition of nuclear factor-kappaB-dependent inflammatory responses by cell type-specific mechanisms upon A2A adenosine receptor gene transfer. Mol Pharmacol. 2004;66(5):1147–1159.
   Web of Science ®Google Scholar
• Kreckler LM, Wan TC, Ge ZD, et al. Adenosine inhibits tumour necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptors. J Exp Pharmacol Ther. 2006;317(1):172–180.
   PubMed Web of Science ®Google Scholar
• Yang D, Zhang Y, Nguyen HG, et al. The A2b adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest. 2006;116:1913–1923.
   PubMed Web of Science ®Google Scholar
• Wilson JM, Ross WG, Agbai ON, et al. The A2A adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol. 2009;182:4616–4623.
   PubMed Web of Science ®Google Scholar
• Sitovsky MV, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol. 2005;5(9):712–721.
   Web of Science ®Google Scholar
• Tasken K, Stokka AJ. The molecular machinery for cAMP-dependent immunomodulation in T-cells. Biochem Soc Trans. 2006;34:476–479.
   Web of Science ®Google Scholar
• Naganuma M, Wiznerowicz EB, Lappas CM, et al. Cutting Edge: critical role for A2A adensine receptors in the T cell-mediated regulation of colitis. J Immunol. 2006;177:2765–2769.
   PubMed Web of Science ®Google Scholar
• Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-g production in murine CD4+ T cells. J Immunol. 2005;174:1073–1080.
   PubMed Web of Science ®Google Scholar
• Csoka B, Himer L, Selmeczy Z, et al. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J. 2008;22(10):3491–3499.
   PubMed Web of Science ®Google Scholar
• Sevigny CP, Li L, Awad AS, et al. Activation of adenosine A2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol. 2007;178:4240–4249.
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Levin RI, Philips M, et al. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol. 1992;148:2201–2206.
   PubMed Web of Science ®Google Scholar
• Zhao ZQ, Sato H, Williams MW, et al. Adenosine A2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium. Am J Physiol. 1996;271:H1456–H1464.
   PubMedGoogle Scholar
• Sullivan GW, Lee DD, Ross WG, et al. Activation of A2a adenosine receptors inhibits expression of alpha4/beta1 integrin (very late antigen-4) on-stimulated human neutrophils. J Leukoc Biol. 2004;75:127–134.
   PubMed Web of Science ®Google Scholar
• Flamand N, Boudreaut S, Picard S, et al. Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Am J Crit Care Med. 2000;161(2 Pt 2):S88–S94.
   Web of Science ®Google Scholar
• Krump E, Borgeat P. Kinetics of 5-lypoxigenase activation, arachidonic acid release, and leukotriene synthesis in human neutrophils: effects of granulocyte-macrophage colony-stimulating factor. Adv Exp Med Biol. 1999;447:107–115.
   PubMedGoogle Scholar
• Krump E, Picard S, Mancini J, et al. Suppression of leukotriene B4 biosynthesis by endogenous adenosine in ligand-activated human neutrophils. J Exp Med. 1997;186(8):1401–1406.
   Web of Science ®Google Scholar
• Cadieux JS, Leclerc P, St-Onge M, et al. Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci. 2005;118 (7):1437–1447.
   Web of Science ®Google Scholar
• Flamand N, Surette ME, Picard S, et al. Cyclic AMP-mediated inhibition of 5-lypoxigenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol. 2002;62(2):250–256.
   Web of Science ®Google Scholar
• Pouliot M, Fiset ME, Massé N, et al. Adenosine up-regulates cyclooxigenase-2 in human granulocytes: impact of the balance of eicosanoid generation. J Immunol. 2002;169 (9):5279–5286.
   Web of Science ®Google Scholar
• McColl SR, St-Onge M, Dussalt AA, et al. Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokine produced by neutrophils. FASEB J. 2006;20(1):187–189.
   Google Scholar
• St-Onge M, Dumas A, Michaud A, et al. Impact of anti-inflammatory agents on the gene expression profile of stimulated human neutrophils: unravelling endogenous resoltution pathways. Plos ONE. 2009;4(3): e4902.
   Web of Science ®Google Scholar
• Yang Z, Day YJ, Toufektsian MC, et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation. 2005;111(17):2190–2197.
   Web of Science ®Google Scholar
• Yang Z, Day YJ, Toufektsian MC, et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation. 2006;114(19):2056–2064.
   PubMed Web of Science ®Google Scholar
• Cerqueira MD. The future of pharmacologic stress: selective A2a adenosine receptor agonists. Am J Cardiol. 2004;94:33D–40D.
   PubMed Web of Science ®Google Scholar
• Odashima M, Otaka M, Jin M, et al. A selective adenosine A2A receptor agonist, ATL-146e, prevents concanavalin A-induced acute liver injury in mice. Biochem Biophys Res Commun. 2006;347(4):949–954.
   Web of Science ®Google Scholar
• Day YJ, Huang L, McDuffie MJ, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest. 2003;112(6):883–891.
   Web of Science ®Google Scholar
• Day YJ, Li Y, Rieger JM, et al. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J Immunol. 2005;174(8):5040–5046.
   Web of Science ®Google Scholar
• Day YJ, Huang L, Ye H, et al. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol. 2006;176(5):3108–3114.
   PubMed Web of Science ®Google Scholar
• Lappas CM, Day YJ, Marshall MA, et al. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med. 2006;203(12):2639–2648.
   PubMed Web of Science ®Google Scholar
• Awad AS, Huang L, Ye H, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Renal Physiol. 2006;290:F828–F837.
   PubMed Web of Science ®Google Scholar
• Montesinos MC, Gadangi P, Longaker M, et al. Wound healing is accelerated by agonists of adensoine A2 (G alpha s-linked) receptors. J Exp Med. 1997;186:1615–1620.
   PubMed Web of Science ®Google Scholar
• Montesinos M, Chen JF, Desai A, et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A2A receptors. Am J Phatol. 2002;160:2009–2018.
   PubMed Web of Science ®Google Scholar
• Victor-Vega C, desai A, Montesinos M, et al. Adenosine A2A agonists promote more rapid wound healing than recombinant human platelet derived growth factor (PDGF). Inflammation. 2002;26:19–24.
   PubMed Web of Science ®Google Scholar
• Katebi M, Soleimani M, Cronstein BN. Adenosine A2A receptors play an active role in mouse bone marrow-derived mesenchymal stem cell development. J Leukoc Biol. 2009;85(3):438–444.
   Web of Science ®Google Scholar
• Trevethick MA, Mantell SJ, Stuart EF, et al. Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions. Br J Pharmacol. 2008;155(4):463–474.
   PubMed Web of Science ®Google Scholar
• Fozard JR, Ellis KM, Villela Dantas MF, et al. Effect of CGS21680, a selective A2AAR agonist, on allergic airways inflammation in the rat. Br J Pharma2cAol. 2002;438:183–188.
   Google Scholar
• Bonneau O, Wyss D, Ferretti S, et al. Effect of A2AAR activation in murine models of respiratory disorders. Am J Physiol Lung Cell Mol Physiol. 2006;290:L1036–L1043.
   Web of Science ®Google Scholar
• Nadeem A, Fan M, Ansari HR, et al. Enhanced airway reactivity and inflammation in A2a adenosine receptor-deficient allergic mice. Am J Physiol Lung Cell 2MA ol Physiol. 2007;292(6):L1335–L1344.
   Google Scholar
• Hasko G, Xu DZ, Lu Q, et al. Adenosine A2A receptor activation reduces lung injury in trauma/hemorrhagic shock. Crit Care Med. 2006;34(4):1119–1125.
   Web of Science ®Google Scholar
• Thiel M, Chouker A, Ohta A, et al. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol. 2005;3:e174.
   PubMed Web of Science ®Google Scholar
• Bevan N, Butchers PR, Cousins R, et al. Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino- 2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin -9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor antagonist activity. Eur J Pharmacol. 2007;564(1–3):219–225.
   Web of Science ®Google Scholar
• Luijk B, van den Berge M, Kerstjens HA, et al. Effect of an inhaled adenosine A2A agonist on the allergen-induced late asthmatic response. Allergy. 2008;63(1):75–80.
   PubMed Web of Science ®Google Scholar
• Rimmer J, Peake HL, Santos CM, et al. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2007;37(1):8–14.
   PubMed Web of Science ®Google Scholar
• Mantell SJ, Stephenson PT, Monaghan SM, et al. Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease. Bioorg Med Chem Lett. 2008; 15;18(4):1284–1287.
   Web of Science ®Google Scholar
• Okonkwo DO, Reece TB, Laurent JJ, et al. A comparison of adenosine A2A agonism and methylprednisolone in attenuating neuronal damage and improving functional outcome after experimental traumatic spinal cord injury in rabbits. J Neurosurg Spine. 2006;4(1):64–70.
   Web of Science ®Google Scholar
• Reece TB, Tribble CG, Okonkwo DO, et al. Early adenosine receptor activation ameliorates spinal cord reperfusion injury. J Cardiovasc Med (Hagerstown). 2008;9(4):363–367.
   Web of Science ®Google Scholar
• Sullivan GW, Fang G, Linden J, et al. A2a adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis. 2004;189:1897–1904.
   PubMed Web of Science ®Google Scholar
• Moore CC, Martin EN, Lee GH, et al. An A2a adenosine receptor agonist, ALT313, reduces inflammation and improves survival in murine sepsis models. BMC Infect Dis. 2008;8:141.
   PubMed Web of Science ®Google Scholar
• Nemeth ZH, Csoka B, Wilmanski J, et al. Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol. 2006;176:5616–5626.
   PubMed Web of Science ®Google Scholar
• Sullivan GW, Linden J, Buster BL, et al. Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, Rolipram. J Infect Dis. 1999;180:1550–1560.
   PubMed Web of Science ®Google Scholar
• Odashima M, Otaka M, Jin M, et al. Selective adenosine A receptor agonist, ATL-146e, attenuates stress-induced gastric lesions in rats. J Gastroenterol Hepatol. 2005;20(2):275–280.
   Web of Science ®Google Scholar
• Odashima M, Otaka M, Jin M, et al. Attenuation of gastric mucosal inflammation induced by aspirin through activation of A2A adenosine receptor in rats. World J Gastroenterol. 2006;12(4):568–573.
   Web of Science ®Google Scholar
• Koizumi S, Odashima M, Otaka M, et al. Attenuation of gastric mucosal inflammation induced by indomethacin through activation of the A(2A) adenosine receptor in rats. J Gastroenterol. 2009;44 (5):419–425.
   Web of Science ®Google Scholar